This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks
by Zacks Equity Research
Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.
Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.
5 Low-Beta Stocks to Take Refuge in a Volatile Market
by Zacks Equity Research
We create a strategy that clearly shows that less risky stocks can also generate handsome returns if some parameters are considered.
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.
Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
by Zacks Equity Research
Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.
Zacks.com featured highlights include: Vanda, Turtle Beach, PCM and Turning Point
by Zacks Equity Research
Zacks.com featured highlights include: Vanda, Turtle Beach, PCM and Turning Point
Vanda Pharmaceuticals (VNDA) Beats Q2 Earnings Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 600.00% and -0.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.
Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Endocyte (ECYT) initiates a phase III VISION study for its lead pipeline candidate,-177Lu-PSMA-617, during the second quarter of 2018.
4 Stocks With Recent Price Strength to Enhance Your Returns
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.
Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.
Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up
by Zacks Equity Research
ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
AbbVie Secures FDA Approval for Endometriosis Drug Elagolix
by Zacks Equity Research
AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.
AstraZeneca Sells Atacand's European Rights to Cheplapharm
by Zacks Equity Research
AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.
Allergan's Depression Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label
by Zacks Equity Research
Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.
4 Biotech Bets to Watch as Industry Rebounds in a Month
by Madhu Goel
The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC
by Zacks Equity Research
The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.
J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
by Zacks Equity Research
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?
by Zacks Equity Research
Celgene (CELG) is likely to maintain momentum in the first quarter on the strength of its lead drug, Revlimid despite recent failures.
Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?
by Zacks Equity Research
In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.